Cryotherapy for inflammation — what the evidence actually supports.

Acute inflammation is the body's normal repair response to tissue stress. After intense exercise, micro-tears in muscle fibers trigger an inflammatory cascade — neutrophils arrive, cytokines signal for repair, swelling occurs, and soreness follows. This process resolves on its own within 24 to 72 hours and is part of how adaptation works. Chronic systemic inflammation is different: the immune system remains in a low-grade activated state for weeks, months, or years, driven by autoimmune dysfunction, metabolic imbalance, gut permeability, or sustained physiological stress. The inflammatory markers stay elevated (CRP, IL-6, TNF-alpha) even without an acute trigger. These are fundamentally different problems, and a modality's effect on one does not predict its effect on the other.

The primary anti-inflammatory pathway in cold exposure runs through norepinephrine. Whole-body cryotherapy produces a sharp increase in circulating norepinephrine — typically 200 to 300 percent above baseline — within minutes of exposure. Norepinephrine inhibits the production of several pro-inflammatory cytokines, including TNF-alpha, and stimulates the production of anti-inflammatory cytokines such as IL-10. This is a real, measurable, reproducible effect. The question is not whether the mechanism exists — it does — but whether the magnitude and duration of the effect are clinically meaningful for specific conditions, and whether repeated sessions compound the benefit over time.

Multiple studies have measured inflammatory markers before and after cryotherapy series (typically 10 to 20 sessions over two to four weeks). The consistent finding is a reduction in circulating TNF-alpha, IL-1beta, and CRP, with an increase in IL-10 and IL-1 receptor antagonist. These changes are statistically significant in most studies but modest in absolute terms. The pattern suggests that repeated whole-body cryotherapy nudges the inflammatory balance toward resolution rather than dramatically suppressing it. For acute post-exercise inflammation, a single session produces a transient anti-inflammatory window that can reduce perceived soreness; for chronic inflammation, the signal appears to require accumulation over multiple sessions.

Rheumatoid arthritis has the most clinical data of any inflammatory condition in the cryotherapy literature. Several controlled trials — notably Hirvonen et al. (2006) and Guillot et al. (2014) — used whole-body cryotherapy as an adjunct to standard RA treatment and found reductions in disease activity scores, joint pain, and morning stiffness compared to control groups. The effect sizes are moderate, the sample sizes are small (typically 30 to 60 participants), and the improvements occurred alongside continued pharmaceutical treatment — not as a replacement. The evidence supports cryotherapy as a complementary modality in RA management, not as a standalone treatment.

Fibromyalgia studies show consistent subjective improvement — reduced pain scores, better sleep quality, improved mood — after cryotherapy series of 10 to 15 sessions. Rivera et al. (2018) and Bettoni et al. (2013) are representative. The challenge is that fibromyalgia is difficult to study: outcomes are largely subjective, placebo response rates are high, and most cryo studies lack sham controls (a fake cryotherapy experience is hard to construct). The signal is positive but the study quality is not strong enough to draw firm conclusions. Practitioners considering cryotherapy for fibromyalgia should treat it as an experimental complement to their existing care plan, discussed with their physician.

A smaller body of research examines cryotherapy for ankylosing spondylitis and related axial inflammatory conditions. Stanek et al. (2015) reported improvements in disease activity and functional capacity after a two-week cryotherapy series. The results are encouraging but come from a single research group with small samples and no long-term follow-up. Replication by independent groups is needed before the evidence can be considered robust. The biological plausibility is sound — the same norepinephrine-mediated anti-inflammatory pathway applies — but plausibility and proof are different things.

The cryotherapy-and-inflammation literature has a consistent quality problem. Most studies are small (under 60 participants), short-term (two to four weeks of treatment with minimal follow-up), and lack adequate control groups. Blinding is nearly impossible — participants know whether they entered a −110 °C chamber — which inflates placebo effects. Publication bias likely favors positive results. Several of the most-cited studies come from a small number of research groups in Poland and Germany, and independent replication has been limited. None of this means the findings are wrong; it means they are preliminary and should be interpreted with appropriate caution.

The biological mechanism is real and well-characterized. The clinical evidence is most supportive for rheumatoid arthritis as an adjunct to standard care, moderately supportive for fibromyalgia with caveats about study quality, and early-stage for other inflammatory conditions. Cryotherapy should not replace any prescribed anti-inflammatory treatment. It should be discussed with a physician before starting, especially for anyone on immunosuppressive medication. And the expectation should be modest — a complement that may reduce symptoms at the margins, not a cure or a primary treatment. Studios that position cryotherapy as a solution for inflammation without these qualifiers are overstating the evidence.